Accountability Lab Community of Practice

Menu

Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal

By /

Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing $4.8 billion equity value.

Was this article helpful?
YesNo

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Scroll to Top